Abel S - Search Results

1

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. Walker DK, et al. Among authors: abel s. Drug Metab Dispos. 2005 Apr;33(4):587-95. doi: 10.1124/dmd.104.002626. Epub 2005 Jan 13. Drug Metab Dispos. 2005. PMID: 15650075 Clinical Trial.

2

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.

Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, Muirhead GJ. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):5-18. doi: 10.1111/j.1365-2125.2008.03130.x. Br J Clin Pharmacol. 2008. PMID: 18333861 Free PMC article. Clinical Trial.

3

Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man.

Abel S, Beaumont KC, Crespi CL, Eve MD, Fox L, Hyland R, Jones BC, Muirhead GJ, Smith DA, Venn RF, Walker DK. Abel S, et al. Xenobiotica. 2001 Aug-Sep;31(8-9):665-76. doi: 10.1080/00498250110052779. Xenobiotica. 2001. PMID: 11569532

4

Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.

Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):19-26. doi: 10.1111/j.1365-2125.2008.03132.x. Br J Clin Pharmacol. 2008. PMID: 18333862 Free PMC article. Clinical Trial.

5

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):27-37. doi: 10.1111/j.1365-2125.2008.03133.x. Br J Clin Pharmacol. 2008. PMID: 18333863 Free PMC article. Clinical Trial.

6

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):38-46. doi: 10.1111/j.1365-2125.2008.03134.x. Br J Clin Pharmacol. 2008. PMID: 18333864 Free PMC article. Clinical Trial.

7

The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):47-53. doi: 10.1111/j.1365-2125.2008.03135.x. Br J Clin Pharmacol. 2008. PMID: 18333865 Free PMC article. Clinical Trial.

8

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.

Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):60-7. doi: 10.1111/j.1365-2125.2008.03137.x. Br J Clin Pharmacol. 2008. PMID: 18333867 Free PMC article. Clinical Trial.

9

Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human.

Beaumont K, Harper A, Smith DA, Abel S. Beaumont K, et al. Among authors: abel s. Xenobiotica. 2000 Jun;30(6):627-42. doi: 10.1080/004982500406453. Xenobiotica. 2000. PMID: 10923864 Clinical Trial.

10

Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.

Rosario MC, Jacqmin P, Dorr P, James I, Jenkins TM, Abel S, van der Ryst E. Rosario MC, et al. Among authors: abel s. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):86-94. doi: 10.1111/j.1365-2125.2008.03140.x. Br J Clin Pharmacol. 2008. PMID: 18333870 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

780 results

Search Page

Filters